BioCentury
ARTICLE | Company News

Humira buoys AbbVie as HCV market share shrinks

July 29, 2016 7:00 AM UTC

AbbVie Inc. (NYSE:ABBV) reported 2Q16 financial results that beat estimates and raised full-year 2016 guidance. Continued strength in sales of autoimmune drug Humira adalimumab allayed some concerns about AbbVie's shrinking market share for its HCV drugs, while the company reiterated that it expects to defend Humira's IP against looming biosimilar competition.

Sales of Humira were $4.1 billion in 2Q16, up from $3.5 billion in 2Q15. The drug accounted for 65% of AbbVie's total 2Q16 sales of $6.45 billion, which rose from $5.5 billion in 2Q15 and beat the $6.2 billion consensus estimate. ...